…
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 69.64M | 79.07M | 83.75M | 87.16M | 56.17M |
| Net income | 53.83M | 64.09M | 72.88M | 74.05M | 50.33M |
| Selling general administrative | 195.66M | 175.94M | 161.47M | 158.90M | 129.16M |
| Gross profit | 407.81M | 421.55M | 399.90M | 378.47M | 300.33M |
| Reconciled depreciation | 61.93M | 55.56M | 47.22M | 53.16M | 43.39M |
| Ebit | 91.11M | 124.29M | 123.31M | 103.08M | 100.22M |
| Ebitda | 153.05M | 179.86M | 169.92M | 164.94M | 143.62M |
| Depreciation and amortization | 61.93M | 55.56M | 46.61M | 61.86M | 43.39M |
| Non operating income net other | - | - | - | -0.30M | -0.49M |
| Operating income | 116.66M | 110.58M | 110.50M | 103.08M | 100.22M |
| Other operating expenses | 863.94M | 838.66M | 771.17M | 753.44M | 624.72M |
| Interest expense | 21.47M | 31.49M | 25.82M | -15.62M | -7.39M |
| Tax provision | 15.81M | 14.98M | 11.31M | 13.11M | 5.84M |
| Net interest income | -21.47M | -31.49M | -25.59M | -15.62M | -7.39M |
| Non recurring | - | - | - | 4.38M | 18.02M |
| Income tax expense | 15.81M | 14.98M | 10.87M | 13.11M | 5.84M |
| Total revenue | 980.60M | 949.25M | 881.66M | 860.90M | 706.79M |
| Total operating expenses | 291.14M | 310.96M | 289.40M | 271.01M | 218.25M |
| Cost of revenue | 572.79M | 527.70M | 481.76M | 482.43M | 406.46M |
| Total other income expense net | -47.02M | -31.52M | -26.75M | -15.92M | -44.05M |
| Net income from continuing ops | 53.83M | 64.09M | 75.63M | 74.05M | 50.33M |
| Net income applicable to common shares | - | - | - | 74.05M | 50.33M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1807.11M | 1388.51M | 1226.06M | 1241.21M | 1227.88M |
| Intangible assets | 180.78M | 185.84M | 145.02M | 175.77M | 220.99M |
| Other current assets | 28.57M | 24.03M | 21.46M | 14.72M | 15.16M |
| Total liab | 492.82M | 642.81M | 552.60M | 663.63M | 706.59M |
| Total stockholder equity | 1314.29M | 745.70M | 673.46M | 577.59M | 521.29M |
| Deferred long term liab | - | - | - | 17.19M | 33.74M |
| Other current liab | 62.67M | 53.86M | 62.55M | 76.37M | 103.33M |
| Common stock | 423.86M | 423.86M | 423.86M | 423.86M | 423.86M |
| Capital stock | 423.86M | 423.86M | 423.86M | 423.86M | 423.86M |
| Retained earnings | 321.38M | 267.55M | 203.46M | 130.58M | 56.53M |
| Other liab | - | - | - | 22.98M | 47.59M |
| Good will | 647.35M | 584.10M | 484.51M | 478.90M | 479.50M |
| Other assets | - | - | - | 19.53M | 17.79M |
| Cash | 380.87M | 113.99M | 105.05M | 100.11M | 117.39M |
| Total current liabilities | 212.37M | 167.79M | 139.18M | 164.52M | 183.94M |
| Current deferred revenue | - | 5.71M | 5.55M | 8.13M | 7.00M |
| Net debt | -39.26M | 357.01M | 299.51M | 376.17M | 362.76M |
| Short term debt | 48.98M | 15.33M | 13.88M | 4.80M | 5.10M |
| Short long term debt | 38.29M | 4.69M | 4.97M | 4.80M | 5.10M |
| Short long term debt total | 341.61M | 471.00M | 404.56M | 476.27M | 480.16M |
| Other stockholder equity | 572.06M | 84.21M | 70.18M | 55.16M | 53.77M |
| Property plant equipment | - | - | - | 103.19M | 135.78M |
| Total current assets | 782.60M | 433.65M | 415.30M | 420.52M | 373.82M |
| Net tangible assets | - | - | - | -77.08M | -179.20M |
| Net receivables | 184.88M | 151.03M | 139.41M | 137.70M | 115.62M |
| Long term debt | 212.54M | 411.95M | 349.40M | 430.66M | 429.36M |
| Inventory | 188.28M | 144.61M | 149.37M | 168.00M | 125.66M |
| Accounts payable | 94.86M | 76.89M | 57.20M | 75.22M | 68.51M |
| Accumulated other comprehensive income | -3.00M | -29.92M | -24.04M | -32.01M | -12.87M |
| Common stock total equity | - | - | - | 423.86M | 423.86M |
| Retained earnings total equity | - | - | - | 130.58M | 56.53M |
| Non currrent assets other | 8.81M | 5.99M | 5.62M | 4.41M | 17.79M |
| Non current assets total | 1024.51M | 954.86M | 810.76M | 820.69M | 854.06M |
| Capital lease obligations | 51.08M | 54.36M | 50.19M | 53.92M | 58.94M |
| Long term debt total | - | - | - | 430.66M | 429.36M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -208.19M | -19.89M | -42.54M | -306.70M |
| Change to liabilities | - | - | - | 30.82M | 24.38M |
| Total cashflows from investing activities | -74.32M | -208.19M | -19.89M | -42.54M | -306.70M |
| Net borrowings | -282.92M | 66.93M | -86.55M | 8.42M | 247.62M |
| Total cash from financing activities | 276.33M | 56.94M | -97.85M | -60.15M | 204.75M |
| Change to operating activities | - | - | - | -3.77M | 17.42M |
| Net income | 53.83M | 64.09M | 72.88M | 74.05M | 50.33M |
| Change in cash | 266.88M | 8.94M | 4.95M | -17.29M | -7.66M |
| Begin period cash flow | 113.99M | 105.05M | 100.11M | 117.39M | 125.05M |
| End period cash flow | 380.87M | 113.99M | 105.05M | 100.11M | 117.39M |
| Total cash from operating activities | 64.06M | 158.51M | 120.08M | 90.78M | 94.62M |
| Issuance of capital stock | 614.39M | 0.00M | 0.00M | - | - |
| Depreciation | 61.93M | 55.56M | 46.61M | 53.16M | 43.39M |
| Other cashflows from investing activities | 5.60M | 0.17M | 0.07M | -22.90M | -2.00M |
| Change to inventory | -36.10M | 4.78M | 11.37M | -48.55M | -19.08M |
| Change to account receivables | -27.27M | -6.19M | -0.13M | -23.25M | -25.36M |
| Sale purchase of stock | -39.28M | -9.71M | -10.56M | -10.00M | 0.00M |
| Other cashflows from financing activities | -11.15M | -9.99M | -0.74M | 8.88M | 237.13M |
| Change to netincome | - | - | - | 7.52M | 27.91M |
| Capital expenditures | 15.63M | 17.16M | 19.96M | 19.64M | 19.98M |
| Change receivables | - | - | - | -23.25M | -25.36M |
| Cash flows other operating | - | - | - | -2.98M | -5.54M |
| Cash and cash equivalents changes | - | - | - | -11.92M | -7.33M |
| Change in working capital | -75.13M | 18.92M | -21.33M | -44.74M | -27.01M |
| Stock based compensation | 29.54M | 23.31M | 25.59M | 23.11M | 25.61M |
| Other non cash items | 2.74M | 12.55M | 11.05M | 3.85M | 6.25M |
| Free cash flow | 48.43M | 141.35M | 100.11M | 71.14M | 74.65M |
Sector: Technology Industry: Scientific & Technical Instruments
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NOVT Novanta Inc |
-0.20 0.17% |
123.50 | 88.04 | 8.39 | 5.08 | 3.27 | 4.72 | 26.77 |
| KYCCF Keyence |
-1.77 0.38% |
470.00 | 41.66 | 38.76 | 0.11 | 5.69 | 0.10 | 0.19 |
| COHR Coherent Corp |
19.90 9.27% |
234.56 | 333.78 | 46.73 | 10.24 | 7.63 | 10.78 | 62.92 |
| GRMN Garmin Ltd |
- -% |
293.93 | 28.91 | 24.45 | 7.01 | 5.99 | 6.72 | 22.32 |
| KEYS Keysight Technologies Inc |
14.18 4.87% |
305.64 | 42.58 | 20.00 | 8.11 | 8.16 | 8.17 | 28.06 |
Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Matthijs Glastra | CEO & Chairman | 1969 |
| Mr. Robert J. Buckley | Chief Financial Officer | 1974 |
| Mr. Brian S. Young | Chief HR Officer | 1969 |
| Mr. Peter L. Chang | Corp. Controller & Chief Accounting Officer | 1965 |
| Ms. Sarah Betadam | Chief Information Officer | NA |
| Ms. Michele Davis Michele Welsh | Gen. Counsel & Corp. Sec. | NA |
| Mr. Charlie Webster | Exec. VP of Novanta Growth System & Global Supply Chain | NA |
| Mr. Chuck Ravetto | Group Pres of Automation Enabling Technologies Group | NA |
| Mr. Heinrich Dreyer | Group Pres of Vision | NA |
| Mr. Ray Nash | Corp. Fin. Leader | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.